Deprescribing Review Found Different Barriers for Patients, Doctors and Nurses

A discontinuation plan can fail for practical and belief-related reasons without demonstrating drug ineffectiveness.

What the publication shows

The systematic review included twenty-three qualitative, quantitative and mixed-method studies on benzodiazepine-receptor-agonist deprescribing in older adults. It coded barriers and enablers into behavioral domains. Beliefs about consequences and capability, resources, goals and social influences varied across stakeholders and settings.

Limits of the evidence

This was not a trial identifying one most effective taper. Some groups, including pharmacists and hospital clinicians, were underrepresented. Populations near the end of life and several specific psychiatric conditions were excluded, restricting applicability.

Application to expert review

For a care review, ask what the patient understood, what support was available and who coordinated follow-up. Distinguish reluctance, withdrawal symptoms and access barriers. The review supports individualized implementation questions rather than inferring nonadherence or prescribing fault from continued use alone.

Source and related reading

Source: Publication PMC9264665. The case-review applications above are interpretive analysis.

Related reading: Cirrhosis Deprescribing Interviews Identify Barriers, Not Proof That Stopping Benzodiazepines Prevents Encephalopathy.